Comparison of Cefoperazone + Sulbactam Versus Polymyxin B in the Management of Ventilator Associated Pneumonias Caused by Multi-Drug Resistant Acinetobacter
Creators
- 1. Intensive Care Unit Saidu Group of Teaching Hospital Swat, Pakistan
- 2. Afridi Medical Complex and Teaching Hospital, Pakistan
- 3. Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan
- 4. Premium International Hospital Islamabad, Pakistan
- 5. Songkla University, Hat-Yai, Thailand
Description
The present study entails a comparative analysis of the efficacy of polymyxin B and cefoperazone with sulbactam in the treatment of pneumonias induced by multidrug-resistant Acinetobacter strains. In the experimental group, the gender distribution was exactly the same (males: 21; females: 15). More co-morbidities exist in Group-II than in Group-I. In groups I and II, the mean ICU stays were respectively 11.86 days plus 2.06 SD and 11.47 days plus 1.61 SD. Day 2 post-therapy saw group mean CPIS at 7.781.48 and group-II at 7.081.23, respectively. The clinical response was seen in group-I (n=11/36) and group-II (n=24/36) patients in accordance with our operational criteria. Similar mortality rates applied to both groups. In line with our hypothesis, 31% (n=9/29) of group I survivors and 65.6% (n=21/32) of group II survivors both showed effectiveness (p=0.007).
Files
193-200.pdf
Files
(396.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:32756cbc48055d0cf65b8b8a210af185
|
396.7 kB | Preview Download |
Additional details
Identifiers
Related works
- Is compiled by
- 10.59890/ijasr.v1i2.482 (DOI)
Dates
- Accepted
-
2023-10-22
References
- Kohbodi GA, Rajasurya V, Noor A. Ventilator-Associated Pneumonia. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
- Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical infectious diseases. 2016;63(5):e61-e111.
- Timsit J-F, Esaied W, Neuville M, Bouadma L, Mourvillier B. Update on ventilator-associated pneumonia. F1000Research. 2017;6.
- Metersky ML, Wang Y, Klompas M, Eckenrode S, Bakullari A, Eldridge N. Trend in ventilator-associated pneumonia rates between 2005 and 2013. Jama. 2016;316(22):2427-9.
- Charles MP, Kali A, Easow JM, Joseph NM, Ravishankar M, Srinivasan S, et al. Ventilator-associated pneumonia. The Australasian medical journal. 2014;7(8):334.